LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Recommendation of “Buy” from Analysts

LENZ Therapeutics, Inc. (NASDAQ:LENZ) has received an average recommendation of “Buy” from the seven brokerages that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $35.40.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of LENZ Therapeutics in a research report on Thursday, November 7th.

Institutional Investors Weigh In On LENZ Therapeutics

Several hedge funds have recently bought and sold shares of LENZ. Dimensional Fund Advisors LP raised its stake in LENZ Therapeutics by 58.0% in the second quarter. Dimensional Fund Advisors LP now owns 37,190 shares of the company’s stock valued at $644,000 after buying an additional 13,653 shares during the period. Renaissance Technologies LLC increased its holdings in shares of LENZ Therapeutics by 28.4% during the 2nd quarter. Renaissance Technologies LLC now owns 60,166 shares of the company’s stock worth $1,040,000 after acquiring an additional 13,300 shares during the last quarter. Marshall Wace LLP bought a new stake in LENZ Therapeutics in the 2nd quarter valued at $390,000. Squarepoint Ops LLC acquired a new stake in LENZ Therapeutics during the 2nd quarter valued at $181,000. Finally, SG Americas Securities LLC bought a new position in LENZ Therapeutics during the third quarter worth $107,000. 54.32% of the stock is currently owned by institutional investors and hedge funds.

LENZ Therapeutics Trading Down 5.3 %

Shares of LENZ stock opened at $25.28 on Monday. The firm’s fifty day moving average price is $28.45 and its two-hundred day moving average price is $26.92. LENZ Therapeutics has a 1 year low of $14.42 and a 1 year high of $38.93.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.